15.90 +0.01 (0.06%)
After hours: 4:56PM EDT
|Bid||15.80 x 1400|
|Ask||15.96 x 3100|
|Day's Range||15.38 - 15.93|
|52 Week Range||7.15 - 18.78|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Array Biopharma moved sharply higher on Thursday in a move that could break its downtrend, but traders will be watching these key levels ahead.
Understanding how Array BioPharma Inc (NASDAQ:ARRY) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...
The Boulder, Colorado-based company said it had a loss of 11 cents per share. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 21. Index (PMI) data, output in the Healthcare sector is rising.
After eking out a modest gain in the week ended April 27, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) pulled back this week amid some not-so-encouraging earnings reports and negative regulatory ...
With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
In this article I am going to calculate the intrinsic value of Array BioPharma Inc (NASDAQ:ARRY) using the discounted cash flows (DCF) model. Anyone interested in learning a bit moreRead More...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 24. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $268 million.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 24. Index (PMI) data, output in the Healthcare sector is rising.
Array BioPharma (ARRY) needs investors to pay close attention to the stock based on moves in the options market lately.
Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget
Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Array BioPharma Inc (NASDAQ:ARRY), with a market capitalization of $2.93B, rarely draw their attention from the investingRead More...
A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday. The oral drugs, encorafenib and binimetinib, are awaiting a U.S. approval decision by June 30 based on promising data on their ability to stall disease worsening, or progression-free survival (PFS). The Array combination - 450 milligrams of encorafenib once daily and 45 mg of binimetinib twice a day - led to median overall survival of 33.6 months in patients with advanced melanoma with a BRAF mutation, meaning half the patients were still alive nearly three years after treatment.
The Boulder, Colorado-based company said it had a loss of 17 cents per share. The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...